Skip to main content

Laura García Latorre

I am a TSS (Higher Health Laboratory Technician). I started my professional career at the ICS in 1987 working at the Good Shepherd Laboratory and in 1992 I joined the Vall d'Hebron Hospital. The Biochemistry laboratory was the first service I was in and shortly afterwards I passed CIBBIM. In all these years I have seen and experienced the transformation of the campus. I am currently continuing at CIBBIM-Nanomedicina specifically in the DDT group which has a laboratory located in the Collserola VHIR building and another in the Mediterrània VHIR building.

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
CIBBIM
General Hospital

Laura García Latorre

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
CIBBIM
General Hospital

I am a TSS (Higher Health Laboratory Technician). I started my professional career at the ICS in 1987 working at the Good Shepherd Laboratory and in 1992 I joined the Vall d'Hebron Hospital. The Biochemistry laboratory was the first service I was in and shortly afterwards I passed CIBBIM. In all these years I have seen and experienced the transformation of the campus. I am currently continuing at CIBBIM-Nanomedicina specifically in the DDT group which has a laboratory located in the Collserola VHIR building and another in the Mediterrània VHIR building.

During all these years I have worked with different biological samples and I have carried out different test techniques
- Biochemistry: Detection of general clinical biochemistry parameters (routine biochemistry).
Quantification of electrolytes, specific lipids, hormones, proteinograms and immunological techniques in blood. Mass spectrometry techniques: metabolic studies in urine (nitrogen balance), detection of Helicobacter pylori in breath. Preparation of parenteral nutrition and its control in experimental animals Quantification of amino acids by HPLC in tissues. Fluoroimmunoassay. nephelometry

- Molecular biology. Bacteria growth. Gene cloning and sequencing. Extraction, quantification and analyzes of DNA, RNA and proteins. qRT-PCR. Western blot. Processing of tissue samples and subsequent lipid extraction. Enzyme activities. Electrophoresis with radioactive isotopes

- Cell biology. Culture of tumor cell lines. Primary cultures of skin biopsies and Amniotic Fluid. Cell viability and proliferation assays, cell cycle and apoptosis analyses. Flow cytometry.

- Pathological anatomy. Immunohistochemistry.

- ISO9001: Quality Management Systems

Projects

(Nano) systems with active targeting to sensitize colorectal cancer stem cells to anti-tumoral treatment Target4Cancer

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Joaquin Seras Franzoso, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 143385
Reference: AC15/00092
Duration: 01/01/2016 - 30/09/2019

Grup de direccionament i alliberament farmacològic

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua, Montse Capella Tomás, José García Arumí, Laura García Latorre, José Raul Herance Camacho
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 1394
Duration: 01/01/2014 - 31/12/2016

Liberación dirigida de nanoconjugados de inhibidor de Alox5 contra células madre tumorales

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 171215
Reference: PI14/02079
Duration: 01/01/2015 - 31/12/2017

Targetting Combined Therapy to Cancer Stem Cells (NANOSTEM)

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre
Funding agency: Instituto de Salud Carlos III
Funding: 145540.01
Reference: PI11/01079
Duration: 01/01/2012 - 31/12/2014

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.